RJA
GMAB icon

Raymond James & Associates’s Genmab GMAB Stock Holding History

Raymond James & Associates’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$4.14M Buy
169,747
+3,598
+2% +$96.2K ﹤0.01% 1778
2024
Q2 		$4.18M Sell
166,149
-216
-0.1% -$6.12K ﹤0.01% 1712
2024
Q1 		$4.98M Sell
166,365
-24,789
-13% -$728K ﹤0.01% 1584
2023
Q4 		$6.09M Sell
191,154
-5,405
-3% -$170K ﹤0.01% 1402
2023
Q3 		$6.93M Buy
196,559
+2,396
+1% +$91.3K 0.01% 1264
2023
Q2 		$7.38M Sell
194,163
-4,358
-2% -$174K 0.01% 1242
2023
Q1 		$7.5M Buy
198,521
+7,498
+4% +$288K 0.01% 1207
2022
Q4 		$8.1M Sell
191,023
-24,132
-11% -$994K 0.01% 1117
2022
Q3 		$6.91M Sell
215,155
-33,703
-14% -$1.18M 0.01% 1166
2022
Q2 		$8.09M Buy
248,858
+43,043
+21% +$1.39M 0.01% 1092
2022
Q1 		$7.45M Buy
205,815
+34,384
+20% +$1.18M 0.01% 1239
2021
Q4 		$6.78M Buy
171,431
+7,102
+4% +$296K 0.01% 1337
2021
Q3 		$7.18M Buy
164,329
+9,867
+6% +$443K 0.01% 1265
2021
Q2 		$6.31M Buy
154,462
+70,219
+83% +$2.71M 0.01% 1339
2021
Q1 		$2.77M Sell
84,243
-6,290
-7% -$237K ﹤0.01% 1805
2020
Q4 		$3.68M Buy
90,533
+12,002
+15% +$449K ﹤0.01% 1509
2020
Q3 		$2.88M Buy
78,531
+3,081
+4% +$111K ﹤0.01% 1537
2020
Q2 		$2.56M Sell
75,450
-48,064
-39% -$1.31M ﹤0.01% 1574
2020
Q1 		$2.62M Buy
123,514
+3,730
+3% +$83.1K ﹤0.01% 1427
2019
Q4 		$2.67M Buy
119,784
+8,233
+7% +$180K ﹤0.01% 1649
2019
Q3 		$2.26M Buy
+111,551
New +$2.2M ﹤0.01% 1705

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Raymond James & Associates's GMAB Position: Q3 2024 in Review

Raymond James & Associates increased its Genmab (GMAB) stake by 2.2% in Q3 2024, buying an estimated $96.2K and bringing the position to 169,747 shares worth $4.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1778.

Raymond James & Associates first reported a position in GMAB in Q3 2019 and has held it in 21 quarters since. The position peaked at $8.1M in Q4 2022. 223 funds tracked by Wall St. Rank hold GMAB as of Q3 2024.

  • Raymond James & Associates held 169,747 shares of Genmab worth $4.14M as of Q3 2024.
  • Raymond James & Associates bought 3,598 Genmab shares in Q3 2024, an estimated $96.2K.
  • Genmab made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1778 holding.
  • Raymond James & Associates first reported a position in Genmab in Q3 2019 and has held it in 21 quarters since.
  • Raymond James & Associates's Genmab position peaked at $8.1M in Q4 2022.
  • 223 funds tracked by Wall St. Rank held Genmab as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.